Market Cap | 15M | P/E | - | EPS this Y | 82.90% | Ern Qtrly Grth | - |
Income | -7.85M | Forward P/E | -3.98 | EPS next Y | 46.20% | 50D Avg Chg | 16.00% |
Sales | 18.53M | PEG | 27.09 | EPS past 5Y | - | 200D Avg Chg | 5.00% |
Dividend | N/A | Price/Book | 1.56 | EPS next 5Y | -0.47% | 52W High Chg | -68.00% |
Recommedations | 2.00 | Quick Ratio | 2.36 | Shares Outstanding | 26.52M | 52W Low Chg | 94.00% |
Insider Own | 17.72% | ROA | -34.35% | Shares Float | 14.72M | Beta | 0.70 |
Inst Own | 17.70% | ROE | -83.36% | Shares Shorted/Prior | 299.69K/336.29K | Price | 0.72 |
Gross Margin | 68.58% | Profit Margin | -42.40% | Avg. Volume | 375,933 | Target Price | 4.90 |
Oper. Margin | -39.85% | Earnings Date | Nov 7 | Volume | 65,176 | Change | -1.93% |
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, Germany, China, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. Its products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products to orthotics and prosthetics providers, the Veterans Health Administration, rehabilitation hospitals and surgery centers, as well as through distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.
Maxim Group | Buy | May 25, 23 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Morris Milton Mayo | Director Director | Sep 08 | Buy | 1.0578 | 15,000 | 15,867 | 77,933 | 09/11/23 |
GUDONIS PAUL R | Chief Executive Offi.. Chief Executive Officer | Aug 30 | Buy | 0.7446 | 48,400 | 36,039 | 878,245 | 08/31/23 |
Kovelman Harry | Chief Medical Office.. Chief Medical Officer | Aug 29 | Buy | 0.60 | 8,333 | 5,000 | 149,556 | 08/30/23 |
Crowley Thomas Aloysius Jr. | Director Director | Jun 06 | Sell | 2.04 | 12,901 | 26,318 | 06/30/23 | |
Mitchell Micah | Chief Commerical Off.. Chief Commerical Officer | Jan 17 | Buy | 0.325 | 15,384 | 5,000 | 64,815 | 01/18/23 |
HENRY DAVID A | Chief Financial Offi.. Chief Financial Officer | Jan 17 | Buy | 0.325 | 76,923 | 25,000 | 163,527 | 01/18/23 |
GUDONIS PAUL R | Chief Executive Offi.. Chief Executive Officer | Jan 17 | Buy | 0.325 | 307,692 | 100,000 | 483,345 | 01/18/23 |
HENRY DAVID A | Chief Financial Offi.. Chief Financial Officer | Nov 22 | Buy | 0.5511 | 9,000 | 4,960 | 86,604 | 11/22/22 |
Crowley Thomas Aloysius Jr. | Director Director | Aug 05 | Sell | 1.711 | 7,141 | 12,218 | 12,901 | 08/08/22 |
GUDONIS PAUL R | Chief Executive Offi.. Chief Executive Officer | Mar 14 | Buy | 4.217 | 5,000 | 21,085 | 92,018 | 03/16/22 |
GUDONIS PAUL R | Chief Executive Offi.. Chief Executive Officer | Mar 11 | Buy | 4.6291 | 5,000 | 23,146 | 87,018 | 03/11/22 |